Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
RBC Capital analyst Brian Abrahams maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Outperform and lowers the price ta...
- SEC Filing
Karyopharm Therapeutics (NASDAQ:KPTI) affirms FY2025 sales outlook from $140.000 million-$155.000 million to $140.000 million-$...
Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(3.82) per share which missed the analyst consensus estimat...
HC Wainwright & Co. analyst Robert Burns upgrades Karyopharm Therapeutics (NASDAQ:KPTI) from Neutral to Buy and announce...
Piper Sandler analyst Edward Tenthoff reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Overweight and lowers the pric...
